Table 1_Dose-dependent adverse events of esketamine in treatment-resistant depression: a s

Nine randomized controlled trials involving 1,449 patients form the basis of this meta-analysis on esketamine safety. The study, authored by Yang Qu and published on figshare in 2026, found a significant, dose-dependent increase in risks for nine adverse events, including nausea and dissociation. It reports that high-dose groups showed a relative risk for dissociation of 10.65 compared to 3.27 in low-dose groups.

Use Cases

• Analyze dose-response relationships for adverse events based on dosage ranges from 28 to 84 mg.
• Compare safety profiles across geographic regions based on subgroup analyses of Mainland China versus international studies.
• Assess the risk-benefit trade-off of esketamine based on reported clinical response rates and treatment discontinuation rates.

Strengths

• Analysis is based on 9 randomized controlled trials, a standard for clinical evidence.
• Includes data from 1,449 patients, providing a substantive sample size for meta-analysis.
• Provides specific relative risk figures for adverse events like nausea (RR 3.72 vs 1.69) across dose groups.

Limitations

• The dataset is a 16.6 KB document summarizing results; the underlying trial data is not provided.
• Row count and column-level documentation for any source data are unknown.
• Freshness should be verified as the last update is dated 2026-05-28.

Provenance

Source

Systematic review and meta-analysis by author Yang Qu, sourced from figshare.

Collection Method

Data was gathered by searching PubMed, Embase, Cochrane Library, CBM, CNKI, and Wanfang databases for randomized controlled trials.

Time Range

Searched from database inception to March 2025.

Freshness

Last updated 2026-05-28 06:23:30

Geography

Studies included are from Mainland China and international multi-regional sources.